UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Molecular Measurable Residual Disease (MRD) Clearance (≤1%) Is Associated with Improved Clinical Outcomes in Patients with Higher-Risk Myelodysplastic Neoplasms (HR-MDS): An Exploratory Analysis of Stimulus-MDS1 in Patients Receiving Sabatolimab or Placebo + Hypomethylating Agent (HMA)

Blood, 2023-11, Vol.142 (Supplement 1), p.3236-3236

2023

Volltextzugriff (PDF)

A Randomized, Double-Blind, Placebo-Controlled, Phase II Study of MBG453 Added to Hypomethylating Agents (HMAs) in Patients (pts) with Intermediate, High, or Very High Risk Myelodysplastic Syndrome (MDS): Stimulus-MDS1

Blood, 2019-11, Vol.134 (Supplement_1), p.4259-4259

2019

Volltextzugriff (PDF)

Asciminib in Newly Diagnosed Chronic Myeloid Leukemia

The New England journal of medicine, 2024-09, Vol.391 (10), p.885-898

2024

Volltextzugriff (PDF)

AML-484 First Results of a Phase II Study (STIMULUS-AML1) Investigating Sabatolimab + Azacitidine + Venetoclax in Patients With Newly Diagnosed Acute Myeloid Leukemia (ND AML)

Clinical lymphoma, myeloma and leukemia, 2022-10, Vol.22, p.S255

2022

Volltextzugriff (PDF)

ASC4FIRST, a Pivotal Phase 3 Study of Asciminib (ASC) vs Investigator-Selected Tyrosine Kinase Inhibitors (IS-TKIs) in Newly Diagnosed Patients With Chronic Myeloid Leukemia (CML): Primary Results

Clinical lymphoma, myeloma and leukemia, 2024-09, Vol.24, p.S154-S154

2024

Volltextzugriff (PDF)

CML-387 ASC4FIRST, a Pivotal Phase 3 Study of Asciminib (ASC) vs Investigator-Selected Tyrosine Kinase Inhibitors (IS-TKIs) in Newly Diagnosed Patients With Chronic Myeloid Leukemia (CML): Primary Results

Clinical lymphoma, myeloma and leukemia, 2024-09, Vol.24, p.S369-S370

2024

Volltextzugriff (PDF)

ASC4FIRST, a Pivotal Phase 3 Study of Asciminib (ASC) vs Investigator-Selected Tyrosine Kinase Inhibitors (IS-TKIs) in Newly Diagnosed Patients With Chronic Myeloid Leukemia (CML): Primary Results

Clinical lymphoma, myeloma and leukemia, 2024-09, Vol.24, p.S187-S187

2024

Volltextzugriff (PDF)

The STIMULUS Program: Clinical Trials Evaluating Sabatolimab (MBG453) Combination Therapy in Patients (Pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS) or Acute Myeloid Leukemia (AML)

Blood, 2020-11, Vol.136 (Supplement 1), p.45-46

2020

Volltextzugriff (PDF)

Phase II Study of Everolimus in Patients with Metastatic Colorectal Adenocarcinoma Previously Treated with Bevacizumab-, Fluoropyrimidine-, Oxaliplatin-, and Irinotecan-Based Regimens

Clinical cancer research, 2013-07, Vol.19 (14), p.3987-3995

2013

Volltextzugriff (PDF)

Poster: AML-484 First Results of a Phase II Study (STIMULUS-AML1) Investigating Sabatolimab + Azacitidine + Venetoclax in Patients With Newly Diagnosed Acute Myeloid Leukemia (ND AML)

Clinical lymphoma, myeloma and leukemia, 2022-10, Vol.22, p.S125

2022

Volltextzugriff (PDF)

Sabatolimab plus hypomethylating agents in previously untreated patients with higher-risk myelodysplastic syndromes (STIMULUS-MDS1): a randomised, double-blind, placebo-controlled, phase 2 trial

The Lancet. Haematology, 2024-01, Vol.11 (1), p.e38-e50

2024

Volltextzugriff (PDF)

AML-187: The STIMULUS Clinical Trial Program: Evaluating Combination Therapy with MBG453 in Patients with Higher-Risk Myelodysplastic Syndrome (HR-MDS) or Acute Myeloid Leukemia

Clinical lymphoma, myeloma and leukemia, 2020-09, Vol.20, p.S188-S188

2020

Volltextzugriff (PDF)

Impact physiologique et comportemental d’un programme de majoration de l’utilisation des escaliers au quotidien chez des membres du personnel de l’hôpital Erasme (Bruxelles)

Kinésithérapie, la revue, 2013-02, Vol.13 (134), p.44-44

2013

Volltextzugriff (PDF)

RESPONSE: A randomized, open-label, phase III study of ruxolitinib in polycythemia vera (PV) patients resistant to or intolerant of hydroxyurea (HU)

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.TPS6643-TPS6643

2012

Volltextzugriff (PDF)

Prediction of stature from hand measurements

Forensic science international, 1990-07, Vol.46 (3), p.181-187

1990

Volltextzugriff (PDF)

Histomorphological changes in the cornea of the rat following monocular eyelid closure

Anatomy, 2016-08, Vol.10 (2), p.87-93

2016

Volltextzugriff (PDF)

Constructability assessment using fuzzy logic modeling: Case of selecting construction system

Malek, Maged Kamel

1996

Volltextzugriff (PDF)

R2M Index 1.0: Assessing the Practical Relevance of Academic Marketing Articles

Journal of marketing, 2021-09, Vol.85 (5), p.22-41

2021

Volltextzugriff (PDF)

Evaluation of hepatitis E antigen kinetics and its diagnostic utility for prediction of the outcomes of hepatitis E virus genotype 1 infection

Virulence, 2021-12, Vol.12 (1), p.1334-1344

2021

Volltextzugriff (PDF)

Collisional excitation of propargylimine by helium: new ab initio 3D-potential energy surfaces and scattering calculations

Physical chemistry chemical physics : PCCP, 2024-09

2024

Volltextzugriff (PDF)

Impacts of investor's sentiment, uncertainty indexes, and macroeconomic factors on the dynamic efficiency of G7 stock markets

Quality & quantity, 2024-06, Vol.58 (3), p.2855-2886

2024

Volltextzugriff (PDF)

Mutation in noncoding RNA RNU12 causes early onset cerebellar ataxia

Annals of neurology, 2017-01, Vol.81 (1), p.68-78

2017

Volltextzugriff (PDF)

Dynamic efficiency in MENA stock markets during COVID-19 outbreak and vaccines

International journal of emerging markets, 2024-01

2024

Volltextzugriff (PDF)

Deltamethrin induced oxidative stress in kidney and brain of rats: Protective effect of Artemisia campestris essential oil

Biomedicine & pharmacotherapy, 2017-10, Vol.94, p.955-963

2017

Volltextzugriff (PDF)

1 – 25 von 86

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(76)
Mit Volltextzugriff
(73)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(40)
Life Sciences & Biomedicine
(27)
Humans
(26)
Female
(23)
Male
(18)
Aged
(14)
Adult
(13)
Middle Aged
(11)
Technology
(10)
Engineering
(6)
Animals
(5)
Cognitive Radio
(5)
Life Sciences
(5)
Physical Sciences
(5)
Prospective Studies
(5)
Telecommunications
(5)
Treatment Outcome
(5)
Adolescent
(4)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(4)
Compressive Sensing
(4)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Molecular Measurable Residual Disease (MRD) Clearance (≤1%) Is Associated with Improved Clinical Outcomes in Patients with Higher-Risk Myelodysplastic Neoplasms (HR-MDS): An Exploratory Analysis of Stimulus-MDS1 in Patients Receiving Sabatolimab or Placebo + Hypomethylating Agent (HMA)

A Randomized, Double-Blind, Placebo-Controlled, Phase II Study of MBG453 Added to Hypomethylating Agents (HMAs) in Patients (pts) with Intermediate, High, or Very High Risk Myelodysplastic Syndrome (MDS): Stimulus-MDS1

Asciminib in Newly Diagnosed Chronic Myeloid Leukemia

Primary Results of Stimulus-MDS1: A Randomized, Double-Blind, Placebo-Controlled Phase II Study of TIM-3 Inhibition with Sabatolimab Added to Hypomethylating Agents (HMAs) in Adult Patients with Higher-Risk Myelodysplastic Syndromes (MDS)

AML-484 First Results of a Phase II Study (STIMULUS-AML1) Investigating Sabatolimab + Azacitidine + Venetoclax in Patients With Newly Diagnosed Acute Myeloid Leukemia (ND AML)

ASC4FIRST, a Pivotal Phase 3 Study of Asciminib (ASC) vs Investigator-Selected Tyrosine Kinase Inhibitors (IS-TKIs) in Newly Diagnosed Patients With Chronic Myeloid Leukemia (CML): Primary Results

CML-387 ASC4FIRST, a Pivotal Phase 3 Study of Asciminib (ASC) vs Investigator-Selected Tyrosine Kinase Inhibitors (IS-TKIs) in Newly Diagnosed Patients With Chronic Myeloid Leukemia (CML): Primary Results

ASC4FIRST, a Pivotal Phase 3 Study of Asciminib (ASC) vs Investigator-Selected Tyrosine Kinase Inhibitors (IS-TKIs) in Newly Diagnosed Patients With Chronic Myeloid Leukemia (CML): Primary Results

The STIMULUS Program: Clinical Trials Evaluating Sabatolimab (MBG453) Combination Therapy in Patients (Pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS) or Acute Myeloid Leukemia (AML)

Phase II Study of Everolimus in Patients with Metastatic Colorectal Adenocarcinoma Previously Treated with Bevacizumab-, Fluoropyrimidine-, Oxaliplatin-, and Irinotecan-Based Regimens

Poster: AML-484 First Results of a Phase II Study (STIMULUS-AML1) Investigating Sabatolimab + Azacitidine + Venetoclax in Patients With Newly Diagnosed Acute Myeloid Leukemia (ND AML)

Sabatolimab plus hypomethylating agents in previously untreated patients with higher-risk myelodysplastic syndromes (STIMULUS-MDS1): a randomised, double-blind, placebo-controlled, phase 2 trial

AML-187: The STIMULUS Clinical Trial Program: Evaluating Combination Therapy with MBG453 in Patients with Higher-Risk Myelodysplastic Syndrome (HR-MDS) or Acute Myeloid Leukemia

Impact physiologique et comportemental d’un programme de majoration de l’utilisation des escaliers au quotidien chez des membres du personnel de l’hôpital Erasme (Bruxelles)

RESPONSE: A randomized, open-label, phase III study of ruxolitinib in polycythemia vera (PV) patients resistant to or intolerant of hydroxyurea (HU)

Prediction of stature from hand measurements

Histomorphological changes in the cornea of the rat following monocular eyelid closure

Constructability assessment using fuzzy logic modeling: Case of selecting construction system

R2M Index 1.0: Assessing the Practical Relevance of Academic Marketing Articles

Evaluation of hepatitis E antigen kinetics and its diagnostic utility for prediction of the outcomes of hepatitis E virus genotype 1 infection

Collisional excitation of propargylimine by helium: new ab initio 3D-potential energy surfaces and scattering calculations

Impacts of investor's sentiment, uncertainty indexes, and macroeconomic factors on the dynamic efficiency of G7 stock markets

Mutation in noncoding RNA RNU12 causes early onset cerebellar ataxia

Dynamic efficiency in MENA stock markets during COVID-19 outbreak and vaccines

Deltamethrin induced oxidative stress in kidney and brain of rats: Protective effect of Artemisia campestris essential oil

Suchergebnisse filtern